{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:27:51Z","timestamp":1771399671155,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric cancer with liver metastases is generally associated with poor prognosis, and curative treatment is rarely achieved. Recently, the combination of cytotoxic chemotherapy and immune checkpoint inhibitors (ICIs) has shown promise. However, the efficacy of ICIs in treating microsatellite-stable (MSS) gastric cancer remains controversial. Herein, we present a case of advanced MSS gastric cancer with liver and bulky lymph node metastases, in which combination therapy with S-1 plus oxaliplatin (SOX) and nivolumab led to a pathological complete response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 64-year-old man was diagnosed with gastric adenocarcinoma with a solitary liver metastasis (S6) and bulky regional lymph node metastasis. Four cycles of SOX and nivolumab (360 mg every 3 weeks) were administered. Imaging revealed marked tumor regression, and surgery was performed. The patient underwent distal gastrectomy with D2 lymphadenectomy and partial hepatectomy. Pathological evaluation revealed complete tumor regression in the primary lesion, lymph nodes, and liver. The tumor was MSS, Epstein\u2013Barr virus-negative and had a low tumor mutational burden (TMB). Immunohistochemistry showed a mean CD8+ tumor-infiltrating lymphocyte density of 59.5 \u00b1 14.3 cells per high-power field, a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of \u2265 70% (clone 28-8), and a germline TP53 p.R106C mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates that even in MSS gastric cancer with low TMB levels, exceptionally high PD-L1 expression may predict a profound response to ICI-based therapy. The PD-L1 CPS may serve as a critical biomarker independent of TMB or microsatellite-instability status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1750532","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:54:12Z","timestamp":1771397652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological complete response in microsatellite- stable gastric cancer with liver and bulky lymph node metastases after nivolumab-based chemotherapy and surgery: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Kenichi","family":"Nonaka","sequence":"first","affiliation":[{"name":"Department of Digestive Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Maniwa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Takao","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Komura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Mushika","sequence":"additional","affiliation":[{"name":"Department of Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arizumi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Daiyukai Research Institute for Medical Science","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiko","family":"Kusakabe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Daiyukai General Hospital","place":["Ichinomiya, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","article-title":"Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts","volume":"131","author":"Fumet","year":"2020","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry assays for lung cancer: Results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2400230","DOI":"10.1200\/PO.24.00230","article-title":"PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0273","article-title":"Mismatch repair status of gastric cancer and its association with the local and systemic immune response","volume":"24","author":"Shin","year":"2019","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0793-y","article-title":"Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer","volume":"122","author":"Kwak","year":"2020","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/febs.70102","article-title":"Oxaliplatin accelerates immunogenic cell death by activating the cGAS\/STING\/TBK1\/IRF5 pathway in gastric cancer","volume":"292","author":"Zhao","year":"2025","journal-title":"FEBS J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26449","article-title":"Immunological impact of chemotherapy on the tumor microenvironment in gastric cancer","volume":"123","author":"Wei","year":"2021","journal-title":"J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e6873","DOI":"10.1002\/cam4.6873","article-title":"Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization","volume":"13","author":"Mendoza","year":"2024","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"717527","DOI":"10.3389\/fimmu.2021.717527","article-title":"Association analyses of TP53 mutation with prognosis, tumor mutational burden, and immunological features in acute myeloid leukemia","volume":"12","author":"Wen","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000738","article-title":"Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer","volume":"109","author":"Liang","year":"2023","journal-title":"Int J Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","author":"Yoshida","year":"2016","journal-title":"Gastric Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00156-0","article-title":"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11366","article-title":"Pathological complete response by S-1 chemotherapy in advanced gastric cancer","volume":"32","author":"Namikawa","year":"2018","journal-title":"In Vivo"},{"key":"B19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40792-017-0344-9","article-title":"A case of advanced gastric cancer achieved a pathological complete response by chemotherapy","volume":"3","author":"Tada","year":"2017","journal-title":"Surg Case Rep"},{"key":"B20","article-title":"A case of HER2-positive advanced gastric cancer with liver metastasis treated by laparoscopic surgery after chemotherapy and achieved pathological complete response","volume":"50","author":"Shimizu","year":"2023","journal-title":"Gan To Kagaku Ryoho"},{"key":"B21","doi-asserted-by":"publisher","first-page":"107097","DOI":"10.1016\/j.ijscr.2022.107097","article-title":"Long-term survival of HER2 positive gastric cancer patient with multiple liver metastases who obtained pathological complete response after systemic chemotherapy: A case report","volume":"94","author":"Sakaue","year":"2022","journal-title":"Int J Surg Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:54:13Z","timestamp":1771397653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1750532"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1750532","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1750532"}}